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Abstract
Background: Information on treatment outcomes among hospitalized patients with multidrug-resistant tuberculosis (MDR-
TB) and extensively drug-resistant tuberculosis (XDR-TB) are scarce in China.
Methodology/Principal Findings: We conducted this retrospective study to analyze the characteristics and treatment
outcomes in MDR- and XDR-TB patients in the 309 Hospital in Beijing, China during 1996–2009. Socio-demographic and
clinical data were retrieved from medical records and analyzed. Logistic regression analysis was performed to identify risk
factors associated with poor treatment outcomes and Cox proportional hazards regression model was further used to
determine risk factors associated with death in TB patients. Among the 3,551 non-repetitive hospitalized TB patients who
had drug susceptibility testing (DST) results, 716 (20.2%) had MDR-TB and 51 (1.4%) had XDR-TB. A total of 3,270 patients
who had medical records available were used for further analyses. Treatment success rates (cured and treatment
completed) were 90.9%, 53.4% and 29.2% for patients with non-MDR-TB, patients with MDR-TB excluding XDR-TB and
patients with XDR-TB, respectively. Independent risk factors associated with poor treatment outcomes in MDR-TB patients
included being a migrant (adjusted OR= 1.77), smear-positivity at treatment onset (adjusted OR= 1.94) and not receiving 3
or more potentially effective drugs (adjusted OR= 3.87). Independent risk factors associated with poor treatment outcomes
in XDR-TB patients were smear-positivity at treatment onset (adjusted OR= 10.42) and not receiving 3 or more potentially
effective drugs (adjusted OR= 14.90). The independent risk factors associated with death in TB patients were having chronic
obstructive pulmonary disease (adjusted HR= 5.25) and having hypertension (adjusted HR= 4.31).
Conclusions/Significance: While overall satisfactory treatment success for non-MDR-TB patients was achieved, more
intensive efforts should be made to better manage MDR- and XDR-TB cases in order to improve their treatment outcomes
and to minimize further emergence of so-called totally drug-resistant TB cases.
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Introduction
Although significant achievements have been made in control-
ling TB in China over the last decade [1,2], multidrug-resistant
(MDR-) and extensively drug-resistant tuberculosis (XDR-TB)
cases have been widespread, causing a public health problem in
China and worldwide in recent years [3–8]. According to the 2010
WHO report on drug resistance surveillance [8], the estimated
number of MDR-TB cases has reached 440,000 globally in 2008
with nearly 50% of the cases coming from India and China. By
January 2010, 58 countries had reported at least one case of XDR-
TB. The number of deaths caused by MDR-TB was estimated to
be 150,000 in 2008. The latest nationwide baseline survey for TB
drug resistance in China from 2007 to 2008 showed that 8.32% of
pulmonary TB patients in China suffered from MDR-TB and
0.68% from XDR-TB [8].
The treatment of patients with MDR- and XDR-TB is more
complex, toxic and costly and less effective than treatment for other
forms of TB. Also, the treatment outcomes of patients with MDR- and
XDR-TB are greatly variable according to the different settings and
regions of the world [9–20]. A better understanding of risk factors
associated with poor treatment outcomes amongMDR- andXDR-TB
patients would be useful to provide better case management. Such data
among hospitalized TB patients in China are lacking. We performed a
retrospective study to determine the characteristics, treatment
outcomes and risk factors associated with poor treatment outcomes
among patients who were treated for MDR- and XDR-TB from 1996
to 2009 in the 309 Hospital in Beijing, China.
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Methods
Ethics statement
All of the investigation protocols in this study were approved by
the institutional ethics committee of the 309 Hospital, Beijing,
China. Since it was a retrospective study, all the information of
patients was routinely collected and recorded by attending
physicians. Written consent was not required for this study since
only routinely collected information was used, and confidentiality
of clinical and laboratory information of the patients was
maintained. Nevertheless, we obtained written informed consent
from patients since the project started in 2009 to provide
information for scientific studies. Permission for using the
information in the medical records of the patients for research
purposes was obtained from the 309 Hospital. The Institute ethics
committee of the 309 Hospital reviewed that relevant ethical issues
in this study were well considered.
Study subjects and data collection
Beijing includes 18 districts, covering a total area of 16,800 km2.
In 2006, the region held 11,976,900 permanent residents and
5,475,000 migrants from other provinces in China [21]. The 309
Hospital, which has a 244-bed TB centre, is the only TB referral
hospital in the urban area of Beijing. The patients treated in the
309 Hospital are either self-referred or referred here by the
clinicians from the general hospitals, community clinics, as well as
district TB prevention and treatment clinics in Beijing and other
provinces in China.
Drug susceptibility testing (DST) results and medical records of
all TB patients receiving inpatient treatment in our hospital
between July 1, 1996 and July 1, 2009 were retrospectively
reviewed. All hospitalised TB patients with both DST results and
medical records available were included for further analysis. Basic
socio-demographic and clinical characteristics were obtained from
the medical records. Treatment outcomes during the period 1996–
2009 were determined by reviewing the medical records from the
in-patient treatment and out-patient treatment, as well as from the
telephone follow-up protocols. All study patients except for those
who defaulted or were transferred out were monitored for further
deaths for 2 years after the start of the treatment.
M. tuberculosis cultures and drug susceptibility testing
Specimens were routinely collected from confirmed or
suspected TB cases. Acid-fast bacilli (AFB) smear microscopy
was assessed by Ziehl-Neelsen staining. Specimens were cultured
using the BACTEC 960 system (Becton Dickinson Diagnostic
Systems, Sparks, MD, USA) according to the manufacturer’s
instructions. Identification of M. tuberculosis was performed using
p-nitrobenzoic acid and thiophene carboxylic acid hydrazine
resistance tests as well as PCR tests. DST was performed using
the proportion method and Lo¨wenstein-Jensen medium. The
concentrations of the drugs used were as follows: isoniazid (1 mg/
L), rifampin (50 mg/L), ethambutol (5 mg/L), streptomycin
(10 mg/L), pyrazinamide (50 mg/L), ofloxacin (2 mg/L), levo-
floxacin (2 mg/L), kanamycin (10 mg/L), para-aminosalicylic
acid (1 mg/L). Quality control was routinely performed during
DST using the reference strains provided by the National
Institute for the Control of Pharmaceutical and Biological
Products (China). Periodic external quality assessment of the
performance of DST results was conducted by the Tuberculosis
Reference Laboratory (TRL) at the Beijing Research Institute for
Tuberculosis Control. All drugs were obtained from Sigma Life
Science Company (USA).
Definitions
New TB cases were defined as TB patients who had denied
having had any prior anti-TB treatment or who received anti-TB
treatment for 30 days or less. Retreatment TB cases were TB
patients who had been receiving TB treatment for at least 30 days
or who had had documented evidence of prior treatment from the
case report or surveillance database [22]. MDR-TB was defined as
TB with resistance to at least isoniazid and rifampin. XDR-TB
was defined as TB with resistance to at least isoniazid, rifampin, a
fluoroquinolone (e.g. ofloxacin, levofloxacin) and one of three
injectable second-line drugs (capreomycin, kanamycin, and
amikacin) [22,23]. Mono-resistant TB was defined as resistance
to a single first-line anti-TB drug. Poly-resistant TB was defined as
resistance to two or more of the first-line anti-TB drugs, but not to
both isoniazid and rifampin [22]. In this study, non-MDR-TB
cases are all drug-susceptible, mono- and poly-resistant cases and
excluding all MDR- and XDR-TB cases. Migrants and residents
were defined as in a previous study [24]. Briefly, migrants were
defined as individuals from other areas of China who moved to
Beijing. Residents were defined as individuals who had a registered
permanent residence in Beijing. Treatment outcomes were defined
according to the WHO and International Union Against
Tuberculosis and Lung Disease (IUATLD) guidelines with minor
modifications [22,25]. Cured was defined as a patient who had
completed treatment according to program protocol and had been
consistently culture-negative (with at least five results) for the final
12 months of treatment for TB. Definition of completed treatment
was defined as a patient who had completed treatment according
to program protocol but does not meet the definition for cured
because of lack of bacteriological results. Died was defined as a
patient who died for any reason during the course of TB
treatment. Treatment was considered to have failed if two or more
of the five cultures recorded in the final 12 months of therapy were
positive, or if any one of the final three cultures was positive.
Defaulted was defined as a patient whose TB treatment was
interrupted for 2 or more consecutive months for any reason.
Transferred out was defined as a patient who had been transferred
to another reporting and recording unit and for whom the
treatment outcome was unknown. Cured and treatment complet-
ed were combined as treatment success, whereas others were
combined as poor treatment outcomes.
Statistical analysis
All data were analysed using the SPSS software (15.0 version).
Comparisons of categorical variables were performed using the
Pearson Chi-square test to compare different groups. Univariate
and multivariate logistic regression analyses were performed to
evaluate the association between patient characteristics and poor
treatment outcomes. Cox proportional hazards regression model
was used to determine factors associated with risk of death in TB
patients. All variables with a P value,0.20 in the univariate
analysis were included in the multivariate logistic regression
model. A P value of ,0.05 was considered to be statistically
significant.
Results
General characteristics of the study population
From July 1996 to July 2009, 5201 TB patients including 2181
(41.9%) new cases and 3020 (58.1%) retreatment cases received in-
patient treatment for TB in the TB center of the 309 Hospital. Of
these, 3648 (70.1%) patients were culture positive for M. tuberculosis
and were subjected to DST. Ninety-seven patients (2.7%) were
further excluded as a result of non-viable specimens or
MDR and XDR Tuberculosis in Beijing
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contaminated cultures. Of the remaining 3551 patients, 716
(20.2%) had MDR-TB and 51 (1.4%) had XDR-TB. The final
analysis included 3270 patients who had medical records available
(Figure 1). The patients were classified into three groups: non-
MDR-TB (n= 2694), MDR-TB excluding XDR-TB (n= 528),
and XDR-TB (n= 48). Among the 2694 patients in the non-
MDR-TB group, 1321 (49.0%) had drug-susceptible TB, 558
(20.7%) had mono-resistant TB, 663 (24.6%) had poly-resistant
TB and 152 (5.6%) had TB that was resistant to second-line anti-
TB drugs only. We compared the characteristics including sex, age
and treatment history for patients who were included and
excluded from the study population and found no significant
differences between them (data not shown). Although 3 out of the
5201 TB patients tested positive for HIV, all of the 3270 patients
who were included for final analysis were tested negative for HIV.
The median age of the patients was 41.0 years (range 2–99). Most
patients were male (70.1%), aged 15–44 years (56.8%), had
pulmonary TB (92.2%), were smear-positive at treatment onset
(73.0%), had cavitary diseases (54.4%), and were retreatment cases
(57.4%). There were 1421 (43.5%) patients who were Beijing
residents and 1849 (56.5%) migrants from other provinces in
China. We observed a significantly higher percentage of retreat-
ment cases, smear-positive cases, as well as cases with 4 or more
years of TB disease among patients with MDR-TB and XDR-TB
compared to non-MDR-TB patients. There were a much higher
proportion of patients with cavitary disease, chronic obstructive
pulmonary disease, and abnormal liver function among the
patients with XDR-TB compared to patients in the other two
groups. More detailed information on socio-demographic and
clinical patient characteristics are shown in Table 1 and Table 2,
respectively.
Anti-TB drug susceptibility patterns of the TB patients at
treatment initiation
At treatment initiation, 8.7% (46/528) of MDR-TB excluding
XDR-TB patients and 18.8% (9/48) of patients with XDR-TB
showed resistance to all first-line anti-TB drugs. The percentage of
patients with resistance to 5 or more anti-TB drugs was 23.3%
(629/2694), 46.8% (247/528), and 89.6% (43/48), for patients
with non-MDR-TB, patients with MDR-TB excluding XDR-TB,
and patients with XDR-TB respectively. Patients with non-MDR-
TB had median resistance to 3 (range 0–6) anti-TB drugs. Patients
with MDR-TB excluding XDR-TB had median resistance to 4
(range 2–9) anti-TB drugs, whereas those with XDR-TB had
median resistance to 6 (range 4–9) drugs. More detailed
information on patient drug susceptibility pattern is shown in
Table 3.
Anti-TB treatment regimens
There were no established standard guidelines for treating TB
patients in the 309 Hospital before 2001. Since 2001, patients with
culture-confirmed TB were treated according to the National
Tuberculosis Programme (NTP) treatment guidelines. In general,
new pulmonary TB patients received 2 months of treatment with
streptomycin (S) or ethambutol (E), isoniazid (H), rifampin (R), and
pyrazinamide (Z) during the intensive phase and 4 months of
isoniazid and rifampin during the continuation phase (2S(E)HRZ/
4HR). Retreatment cases received 3 months of intensive treatment
and 5 months of continuation treatment according to the following
regimen: 2SHRZE/1HRZE/5HRE. During the study period,
there was no standard treatment strategy to guide the treatment of
MDR-TB patients in the 309 Hospital. In general, at least 3
months of amikacin (AMK) or capreomycin (CPM), thiacetazone
(TH), pyrazinamide, and ofloxacin (OFLX) were prescribed for
the intensive phase, whilst TH and OFLX were prescribed for the
continuation phase. The most recent DST results available suggest
that other drugs such as levofloxacin, moxifloxacin, ciprofloxacin,
and 2 modified forms of rifampin (rifapentine and rifabutin) are
also useful in different combinations. Capreomycin, moxifloxacin,
and rifabutin were introduced into the treatment regimen in 2000,
2005, and 2008, respectively. The remaining drugs that are listed
in Table 3 have been available since 1996. Although the
continuation treatment phase for confirmed MDR-TB cases has
been recommended to be at least 18 months, individualised
regimens were administered based mainly on each individual
patient’s physical and financial situation as well as DST results.
The 3270 study subjects in our study were hospitalised for a
median (range) duration of 213 days (1–605 days). For patients in
the non-MDR-TB group, the median (IQR) in-patient treatment
duration was 6.9 months (3.7–15.5 months), and the median (IQR)
total treatment duration (including in-patient treatment and out-
patient treatment) was 13.6 months (12.5–17.6 months). For
patients in the MDR excluding XDR-TB group, the median
(IQR) in-patient treatment duration was 8.6 months (4.1–17.5
months), and the median (IQR) total treatment duration was 21.9
months (21.1–22.6 months). For patients in the XDR-TB group,
the median (IQR) in-patient treatment duration was 8.9 months
(4.5–18.3 months), and median (IQR) total treatment duration was
22.3 months (20.6–23.4 months). Detailed information on the
drugs used in the treatment regimens, as well as treatment
durations for the study subjects, are shown in Table 3. In general,
patients that had tested negative for any serious underlying
diseases received in-patient treatment during intensive treatment
phase, with out-patient treatment and telephone follow-up being
received during the continuation treatment phase. The test for
sputum-smears and/or cultures was conducted on a monthly basis.
Figure 1. Study population of hospitalized TB cases in the 309
Hospital, July 1996–July 2009. TB= tuberculosis. MDR=multidrug-
resistant. XDR= extensively drug-resistant.
doi:10.1371/journal.pone.0019399.g001
MDR and XDR Tuberculosis in Beijing
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Treatment outcomes of TB patients
A treatment success rate of 84.0% was obtained for the study
population. In comparison with patients with non-MDR-TB (90.9%),
a much lower percentage of MDR-TB patients has successful
treatment, which is 53.4% without XDR-TB and 29.2% with XDR-
TB (Table 4). We also observed a higher percentage of treatment
success for new cases than retreatment cases (Table 5), and for patients
who received treatment after 2001 than before 2001 (Table 5).
Risk factors associated with poor treatment outcomes in
MDR- and XDR-TB patients
Independent risk factors associated with poor treatment
outcomes in MDR-TB patients were migrants (adjusted
OR=1.77, 95% CI, 1.06 to 2.96), smear-positivity at treatment
onset (adjusted OR=1.94, 95% CI, 1.13 to 3.34) and not
receiving 3 or more potentially effective drugs (adjusted
OR=3.87, 95% CI, 2.53 to 5.91). Independent risk factors
associated with poor treatment outcomes in XDR-TB patients
were smear-positivity at treatment onset (adjusted OR=10.42,
95% CI, 1.05 to 103.10) and not receiving 3 or more potentially
effective drugs (adjusted OR=14.90, 95% CI, 1.35 to 164.94)
(Table 6 and Table S1).
Risk factors associated with death in TB patients
Fifty of the 3270 enrolled TB patients died within two years
following the start of the treatment. The median interval from
anti-TB treatment to death was 7.3 months (IQR=3.4–13.9). The
50 deaths occurred proportionally as follows: 31(1.2%) of 2694
patients with non-MDR-TB; 16 (3.0%) of 528 patients with MDR-
TB excluding XDR-TB; and 3 (6.3%) of 48 patients with XDR-
TB. In the Cox multivariate model, having chronic obstructive
pulmonary disease (adjusted HR=5.25, 95% CI, 2.60 to 10.62)
and having hypertension (adjusted HR=4.31, 95% CI, 1.90 to
9.78) were independent risk factors associated with death from any
cause (Table 7 and Table S2).
Discussion
The percentage of MDR-TB (20.2%) and XDR-TB (1.4%)
among patients receiving inpatient treatment in our hospital from
1996 to 2009 was higher than the latest nationwide baseline survey
for TB drug resistance (8.32% for MDR-TB and 0.68% for XDR-
TB, respectively) [8]. The relatively higher prevalence of patients
with MDR- and XDR-TB, and the overall high percentage of
resistance to most of the anti-TB drugs tested could be explained
by the fact that our study subjects were hospitalized TB patients,
Table 1. Socio-demographic characteristics of hospitalized TB patients in the 309 Hospital.
Characteristics Total
Patients with
non-MDR -TB
Patients with
MDR-TB excluding
XDR-TB
Patients with
XDR-TB P
n=3270(%) n=2694 (%) n=528 (%) n=48 (%)
Gender 0.028
Male 2292 (70.1) 1911 (70.9) 345 (65.3) 36 (75.0)
Female 978 (29.9) 783 (29.1) 183 (34.7) 12 (25.0)
Age ,0.001
0–14 18 (0.6) 12 (0.4) 4 (0.8) 2 (4.2)
15–29 974 (29.8) 809 (30.0) 149 (28.2) 16 (33.3)
30–44 884 (27.0) 696 (25.8) 171 (32.4) 17 (35.4)
45–59 668 (20.4) 587 (21.8) 79 (15.0) 2 (4.2)
60–74 451 (13.8) 356 (13.2) 87 (16.5) 8 (16.7)
75– 275 (8.4) 234 (8.7) 38 (7.2) 3 (6.2)
Marital status 0.023
Married 2443 (74.7) 2000 (74.2) 413 (78.2) 30 (62.5)
Single 827 (25.3) 694 (25.8) 115 (21.8) 18 (37.5)
Residence situation 0.143
Beijing Resident 1421 (43.5) 1192 (44.2) 210 (39.8) 19 (39.6)
Migrant 1849 (56.5) 1502 (55.8) 318 (60.2) 29 (60.4)
Living area 0.654
Rural area 1172 (35.8) 961 (35.7) 196 (37.1) 15 (31.2)
Urban area 2098 (64.2) 1733 (64.3) 332 (62.9) 33 (68.8)
Ethnicity 0.571
The largest group (Han) 3153 (96.4) 2600 (96.5) 508 (96.2) 45 (93.8)
Ethnic groups 117 (3.6) 94 (3.5) 20 (3.8) 3 (6.2)
Smoking, yes (n = 3119) 526 (16.9) 443 (17.2) 78 (15.7) 5 (11.9) 0.506
Alcohol abuse, yes (n = 3151) 142 (4.5) 120 (4.6) 20 (4.0) 2 (4.5) 0.857
TB = tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
doi:10.1371/journal.pone.0019399.t001
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and were mainly comprised of long-term (52.6% had 4 or more
years of TB disease), severe (54.4% had cavitary diseases, 73.0%
had positive smear results, and 12.0% had Diabetes mellitus) and
retreatment cases (57.4%).
A study from Taiwan reported the prevalence of MDR- and
XDR-TB as being 5.7% (150/2625) and 0.4% (10/2625)
respectively [26], and another study reported the prevalence of
MDR- and XDR-TB as being 43.1% (261/605) and 5.5% (33/
605) respectively among hospitalized TB patients in Georgia [27].
In our study, a high percentage of new (not previously treated)
MDR-TB (31.4%, 166/528) and XDR-TB (31.3%, 15/48) cases
were observed. A study conducted in Shanghai, another major city
in China, also reported similar results. This latter study reported
that more than half (59.4%, 104/175) of the patients with MDR-
and XDR-TB were newly diagnosed and had no prior history of
TB treatment. This suggests that there was a high ongoing
transmission rate of MDR- and XDR-TB in major cities in China
[15].
Discrepancies regarding the treatment success rates for MDR-
and XDR-TB patients are reported in the literature. Treatment
success rates have been shown to be associated with the degree of
drug resistance and the presence or absence of HIV co-infection
[19]. In the absence of HIV co-infection, the rates of treatment
success in MDR- and XDR-TB reached 89% and 80%
respectively among 125 TB patients with a definitive outcome
in a study conducted in Germany [11]. Similar high treatment
success rates were also observed, for example, in a recent study
carried out in Heilongjiang province of China, the initial
treatment success rates were 88.5% (100/113) and 73.4% (94/
128) for newly diagnosed and retreated MDR-TB cases
respectively [20]. A study in Peru also reported a high treatment
success rate of 71% (10/14) for XDR-TB [12]. Relatively worse
treatment outcomes were observed in some other studies. For
example, the percentage of treatment success was 60.4% (142/
235) for MDR-TB patients and 42.6% (23/54) for XDR-TB
patients from a study in Estonia [14]. In a study conducted in
Shanghai, only 54.9% (96/175) of the MDR-TB patients
diagnosed in district TB hospitals in Shanghai were successfully
treated [15]. In a study from South Africa, 49% (239/491) of the
MDR-TB patients were cured or completed treatment [9].
Although overall treatment outcomes were reported to be
substantially worse when HIV co-infection was also a consider-
ation [17], a recent study from KwaZulu Natal, South Africa has
reported that the number of deaths did not significantly differ in
those patients with HIV infection (41%, 34/82) in comparison
with non-HIV sufferers (30%, 28/92) [18]. In our study, the
overall treatment success rates for MDR- and XDR-TB cases
(53.4% for MDR-TB excluding XDR, and 29.2% for XDR-TB)
were relatively low in comparison with studies from other cities in
China and other countries in the world. In addition, the
Table 2. Clinical characteristics of hospitalized TB patients in the 309 Hospital.
Characteristics Total
Patients with
non-MDR -TB
Patients with
MDR-TB
excluding
XDR-TB
Patients with
XDR-TB P
n=3270(%) n=2694 (%) n=528 (%) n=48 (%)
Sites of TB 0.013
Extrapulmonary TB 256 (7.8) 228 (8.5) 25 (4.7) 3 (6.2)
Pulmonary TB 3014 (92.2) 2466 (91.5) 503 (95.3) 45 (93.8)
Lower lung field TB (n = 3024) 1575 (52.1) 1286 (52.0) 262 (52.0) 27 (60.0) 0.563
TB history ,0.001
New 1392 (42.6) 1211 (45.0) 166 (31.4) 15 (31.2)
Retreatment 1878 (57.4) 1483 (55.0) 362 (68.6) 33 (68.8)
Smear-positivity at treatment onset (n = 2674) 1951 (73.0) 1526 (70.9) 392 (82.2) 33 (75.0) ,0.001
Radiological findings at onset 0.545
Non-cavitary 1492 (45.6) 1239 (46.0) 234 (44.3) 19 (39.6)
Cavitary disease 1778 (54.4) 1455 (54.0) 294 (55.7) 29 (60.4)
Family history of TB, yes (n = 3205) 133 (4.1) 100 (3.8) 31(6.2) 2 (4.3) 0.046
Underlying diseases
Diabetes mellitus 393 (12.0) 331 (12.3) 59 (11.2) 3 (6.2) 0.359
Chronic obstructive pulmonary disease 168 (5.1) 137 (5.1) 22 (4.2) 9 (18.8) ,0.001
Abnormal liver function 190 (5.8) 171 (6.3) 8 (1.5) 11 (22.9) ,0.001
Hepatitis 112 (3.4) 90 (3.3) 19 (3.6) 3 (6.2) 0.532
Malignancy 25 (0.8) 24 (0.9) 1 (0.2) 0 (0.0) 0.198
Hypertension 172 (5.3) 145 (5.4) 22 (4.2) 5 (10.4) 0.142
4 or more previous hospitalization for TB 175 (5.4) 135 (5.0) 36 (6.8) 4 (8.3) 0.157
4 or more years of TB disease 1720 (52.6) 1272 (47.2) 406 (76.9) 42 (87.5) ,0.001
TB = tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
doi:10.1371/journal.pone.0019399.t002
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observation that the treatment outcome is less favorable in
patients with XDR-TB than those with MDR-TB excluding
XDR-TB as observed in our study and others is of concern.
Because XDR-TB cases have even more limited choices of
effective drugs available for treatment, it is highly unlikely that
suitable treatment regimens involving at least three effective TB
drugs can be designed in many cases [28].
We observed a significantly higher proportion of successful
treatment in patients being treated after 2001 than before 2001. The
improved treatment outcomes could be attributed to the fact that
there had been no established standard guidelines for treating TB
patients in the 309 Hospital until 2001, when the National
Tuberculosis Programme (NTP) treatment guidelines were widely
adopted in China. The improved treatment outcomes could also be
Table 3. Anti-TB drugs used in treatment regimens for hospitalized TB patients in the 309 Hospital.
Patients with non-MDR -TB (n=2694)
Patients with MDR-TB excluding XDR-TB
(n =528) Patients with XDR-TB (n =48)
Patients
given drug
Treatment
duration
(months;
median,
IQR)
Resistance
pattern
Patients
given drug
Treatment
duration
(months;
median, IQR)
Resistance
pattern
Patients
given
drug
Treatment
duration
(months;
median,
IQR)
Resistance
pattern
isoniazid 2031 (75.4%) 5.1 (3.0–7.8) 752 (27.9%) 245 (46.4%) 2.2 (1.5–2.9) 528 (100.0%) 28 (58.3%) 2.1 (0.5–3.0) 48 (100.0%)
rifampin 1937 (71.9%) 5.9 (2.3–8.2) 430 (16.0%) 259 (49.1%) 2.3 (1.0–2.6) 528 (100.0%) 26 (54.2%) 2.4 (0.5–3.3) 48 (100.0%)
streptomycin 499 (18.5%) 1.8 (1.0–2.9) 920 (34.1%) 85 (16.1%) 2.2 (1.5–3.0) 274 (51.9%) 13 (27.1%) 2.8 (1.1–3.0) 24 (50.0%)
ethambutol 1644 (61.0%) 5.1 (3.3–6.2) 1004 (37.3%) 326 (61.7%) 6.7 (4.1–14.8) 278 (52.6%) 31 (64.6%) 6.9 (5.8–17.5) 23 (47.9%)
pyrazinamide 1396 (51.8%) 2.6 (2.0–4.1) 259 (9.6%) 457 (86.6%) 5.7 (3.6–8.3) 144 (27.3%) 41 (85.4%) 5.1 (3.1–9.6) 15 (31.3%)
ofloxacin 101 (3.7%) 6.0 (2.1–9.2) 200 (7.4%) 84 (15.9%) 9.3 (6.0–18.6) 66 (12.5%) 4 (8.3%) 4.1 (3.3–6.5) 48 (100.0%)
levofloxacin 1427 (53.0%) 8.1 (4.1–15.8) 200 (7.4%) 218 (41.3%) 10.1 (4.0–18.3) 66 (12.5%) 22 (45.8%) 9.5 (3.8–17.3) 48 (100.0%)
kanamycin 237 (8.8%) 2.5 (1.6–4.3) 349 (13.0%) 89 (16.9%) 3.2 (2.1–8.5) 137 (25.9%) 10 (20.8%) 3.2 (0.5–8.4) 48 (100.0%)
para-aminosalicylic
acid
391 (14.5%) 3.1 (2.0–5.6) 650 (24.1%) 265 (50.2%) 6.7 (2.7–7.8) 129 (24.4%) 30 (62.5%) 7.6 (3.1–6.8) 14 (29.2%)
amikacin 187 (6.9%) 4.6 (2.5–9.6) ND 67 (12.7%) 5.9 (3.1–15.6) ND 5 (10.4%) 5.7 (2.0–11.5) ND
capreomycin 0 0 ND 6 (1.1%) 4.0 (2.9–8.7) ND 0 0 ND
Moxifloxacin 0 0 ND 6 (1.1%) 3.1 (2.5–5.5) ND 20 (41.7%) 5.0 (3.7–6.0) ND
Ciprofloxacin 0 0 ND 3 (0.6%) 2.7 (2.0–5.7) ND 0 0 ND
Thiacetazone 1307 (48.5%) 5.2 (3.7–14.1) ND 284 (53.8%) 8.2 (4.3–16.1) ND 29 (60.4%) 8.1 (5.6–16.8) ND
Rifapentin 0 0 ND 225 (42.6%) 2.6 (1.5–4.5) ND 20 (41.7%) 1.8 (1.3–5.9) ND
Rifabutin 0 0 ND 3 (0.6%) 2.4 (1.4–5.1) ND 4 (8.3%) 3.4 (2.0–5.6) ND
TB= tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
doi:10.1371/journal.pone.0019399.t003
Table 4. Comparison of treatment outcomes for hospitalized TB patients in the 309 Hospital.
Treatment outcome
Patients with
non-MDR -TB
Patients with MDR-TB
excluding XDR-TB Patients with XDR-TB Total
n=2694 (%) n=528 (%) n=48 (%) n=3270 (%)
Treatment success 2450 (90.9) 282 (53.4) 14(29.2) 2746(84.0)
Cured 1591 (59.0) 170 (32.2) 5 (10.4) 1766 (54.0)
Treatment completed 859 (31.9) 112 (21.2) 9 (18.8) 980 (30.0)
Poor treatment outcomes 244 (9.1) 246 (46.6) 34 (70.8) 524 (16.0)
Died 31 (1.2) 16 (3.0) 3 (6.3) 50 (1.5)
Failed 132 (4.9) 131 (24.8) 21 (43.8) 284 (8.7)
Defaulted 39 (1.4) 92 (17.4) 9 (18.7) 140 (4.3)
Transferred out 42 (1.6) 7 (1.3) 1 (2.1) 50 (1.5)
TB = tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
doi:10.1371/journal.pone.0019399.t004
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linked to the overall success in TB control achieved in China due to
increased government commitment and more intensive TB control
measures such as covering the WHO Directly Observed Therapy
Short-Course (DOTS) strategy nationwide, strengthening local
public health facilities and national infrastructure [2]. Additionally,
the data from our study also suggested that at least in this setting,
and potentially in other similar settings with high drug resistance,
DOTS programs are important, but it is not a measure sufficient
enough to cure a sufficient number of TB cases with more
complicated forms of TB such as MDR- and XDR-TB. The WHO
guidelines recommend continuing therapy for a minimum of 18
months after culture conversion, and extending therapy to 24
months may be indicated in chronic cases with extensive pulmonary
damage [22]. However, as a result of financial constraints, many
patients with MDR- and XDR-TB in our study could not afford the
cost of treatment and thus had much shorter treatment duration
than would have been advised. In future, more efforts should be
made to provide financial support for those MDR- and XDR-TB
patients who cannot afford ideal individualised treatment regimens.
The proportion of defaulters among MDR-TB (92/528, 17.4%)
and XDR-TB (9/48, 18.7%) patients in our study were close to
that observed in Uzbekistan (12/87, 14% for MDR-TB) [16]. A
higher proportion of defaulters were observed in a few other
studies such as in South Africa (144/491, 29.0% for MDR-TB) [9]
and South Korea (453/1407, 32.0% for MDR-TB) [13]. The high
default rates observed in our study and others deserves important
attention since all of the defaulted MDR- and XDR-TB patients
without adequate treatment in our study had positive culture
results and thus could potentially continue to be sources of
transmission in their communities and threats to global public
health [28]. The prognosis for the defaulted patients was suggested
to be poor by a study reporting that of 47 (70.1%) MDR-TB
patients who defaulted and were successfully traced, 25 (53.2%)
had died [29]. Therefore, minimizing the rate of default is likely to
not only help decrease ongoing transmission of MDR- and XDR-
TB, but also reduce TB-related mortality.
Not receiving 3 or more potentially effective drugs was a risk
factor significantly associated with poor treatment outcomes in
Table 5. Comparison of treatment outcomes for hospitalized TB patients in the 309 Hospital stratified by treatment period
(patients being treated before and after 2001).
Treatment success
Poor treatment
outcomes OR (95%CI) P
Before 2001
Patients with non-MDR -TB
New 27 (71.1) 11 (28.9) 1
Retreatment 117 (84.8) 21 (15.2) 0.44 (0.19,1.02) 0.052
Patients with MDR-TB excluding XDR-TB
New 6 (37.5) 10 (62.5) 1
Retreatment 30 (30.0) 70 (70.0) 1.40 (0.47, 4.20) 0.547
Patients with XDR-TB
New 1 (33.3) 2 (66.7) 1
Retreatment 1 (7.7) 12 (92.3) 6.00 (0.26,140.05) 0.226
After 2001
Patients with non-MDR -TB
New 1088 (92.8) 85 (7.2) 1
Retreatment 1218 (90.6) 127 (9.4) 1.34 (1.00,1.78) 0.048
Patients with MDR-TB excluding XDR-TB
New 89 (59.3) 61 (40.7) 1
Retreatment 157 (59.9) 105 (40.1) 0.98 (0.65, 1.47) 0.906
Patients with XDR-TB
New 4 (33.3) 8 (66.7) 1
Retreatment 8 (40.0) 12 (60.0) 0.75 (0.17,3.35) 0.706
Total
Before 2001
New 34 (59.6) 23 (40.4) 1
Retreatment 148 (59.0) 103 (41.0) 1.03 (0.57, 1.85) 0.924
After 2001
New 1181(88.5) 154 (11.5) 1
Retreatment 1383 (85.0) 244(15.0) 1.35 (1.09, 1.68) 0.006
OR=odds ratio.
CI = confidence interval.
TB = tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
doi:10.1371/journal.pone.0019399.t005
MDR and XDR Tuberculosis in Beijing
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19399
both MDR-TB and XDR-TB patients in this study. Several
studies suggested that extensive DST and the availability of
second- and third-line drugs under inpatient management
conditions permitted relatively high treatment success rates in
MDR- and XDR-TB [11,29,30]. Currently, DST processing may
take as long as several weeks in most clinics, by which time the
patients could have already been treated with mono-therapy
before the initiation of individualized treatment based on the DST
results. Since many TB patients only receive in-patient treatment
for less than 2 months due to financial restrictions, a proportion of
new MDR- and XDR-TB cases will not be promptly diagnosed
during these patients’ hospitalization, affecting the overall TB
treatment success rates. Therefore, rapid methods for early
diagnosis of drug resistant-TB are urgently needed in order to
achieve better treatment outcomes for MDR- and XDR-TB cases.
Migrants from other provinces and smear-positivity were also
risk factors associated with poor treatment outcomes in patients
with MDR-TB. Studies confirmed the migrant population
contribution to the incidence of TB and the differences were
reported among the 18 districts in Beijing [24,31]. As the migrants
posed great challenges on TB control, the Beijing municipal
government has increased its efforts at addressing this issue, for
example, by providing free anti-TB drugs for its migrant
population since 2006. However, the government’s free treatment
policy is only able to cover a small percentage of the patients’ total
costs for TB treatment, as most migrant patients who contract TB
are no longer able to work, this is not a suitable financial solution.
Thus, more effort should be made to improve the social welfare, to
include greater financial subsidies to TB treatment costs for the
poor migrant TB patients. This is likely to achieve better treatment
outcomes. Special attention may also beneficially be paid to
migrant patients, with view to improve the treatment adherence in
Beijing.
Regarding smear-positivity, our observation that having positive
AFB smears at the start of treatment is independently associated
with poor treatment outcomes in MDR-TB cases is in accordance
with the findings from other studies [14,32]. This may be
explained by the fact that smear-positive patients often have more
severe disease and a longer delay before the initiation of the
treatment.
Although several studies have suggested an association between
resistance to fluoroquinolones and poor treatment outcomes in
MDR-TB patients [14,32–34], this was not observed in our study.
In addition, we also did not find any significant association
Table 6. Univariate and multivariate logistic regress analysis of the association of potential risk factors with poor treatment
outcomes in MDR- and XDR-TB patients*.
Potential risk factors Patients with MDR-TB excluding XDR-TB Patients with XDR-TB
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Residence situation
Beijing Resident 1 1 1 1
Migrant 1.90 (1.33, 2.71) ,0.001 1.77 (1.06, 2.96) 0.030 4.32 (1.16,16.15) 0.030 4.58 (0.69, 30.33) 0.115
Living area
Rural area 1 1 1
Urban area 0.60 (0.42, 0.86) 0.005 0.75 (0.46,1.24) 0.265 0.50 (0.12, 2.15) 0.351
Lower lung field TB 1.39 (0.98,1.97) 0.067 1.07 (0.72,1.60) 0.747 1.10 (0.29, 4.21) 0.891
Sites of TB
Extrapulmonary TB 1 1 1
Pulmonary TB 1.91 (0.81,4.50) 0.140 2.06 (0.31,13.64) 0.454 5.50 (0.46, 66.32) 0.180 1.04 (0.05, 24.19) 0.981
Smear-positivity at treatment onset** 1.72 (1.06,2.80) 0.027 1.94 (1.13, 3.34) 0.016 6.72 (1.47, 30.76) 0.014 10.42 (1.05,103.10) 0.045
Radiological findings at onset
Non-cavitary 1 1 1
Cavitary disease 1.50 (1.06,2.12) 0.022 1.49 (0.99,2.24) 0.056 0.79 (0.22, 2.88) 0.725
Diabetes mellitus 0.65 (0.37,1.14) 0.131 0.73 (0.38,1.43) 0.369 0.18 (0.02, 2.19) 0.180 0.20 (0.01,3.38) 0.263
Hypertension 0.32 (0.12,0.89) 0.029 0.63 (0.20,1.96) 0.423 1.73 (0.18,17.05) 0.637
4 or more previous hospitalization for TB 0.55 (0.27,1.13) 0.103 0.53 (0.22,1.14) 0.101 0.00 0.999
Resistance to 3 or more first-line drugs 1.52 (0.92,2.51) 0.105 1.06 (0.59,1.89) 0.852 0.76 (0.17,3.35) 0.714
Not receiving 3 or more potentially
effective drugs
2.77 (1.94,3.96) ,0.001 3.87 (2.53,5.91) ,0.001 8.57 (1.65, 44.43) 0.010 14.90 (1.35, 164.94) 0.028
TB = tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
OR =odds ratio.
CI = confidence interval.
*Variables included in the univariate analysis were shown in Table S1; All variables with a P value,0.2 in the univariate analysis were included in multivariate logistic
regression analysis; 472 MDR-TB patients and 44 XDR-TB patients were included in multivariate logistic regression analysis. A P value of ,0.05 was considered to be
statistically significant.
**n = 477 for MDR-TB; n = 44 for XDR-TB.
doi:10.1371/journal.pone.0019399.t006
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between poor treatment outcomes and a few other variables
previously identified to be risk factors for poor treatment outcomes
in MDR- and XDR-TB patients, including previous TB treatment
[14], alcohol abuse [32], and being male [32] for poor outcomes in
patients with MDR-TB. Patients that were urban residents were at
greater risk of contracting XDR-TB [14]. This disparity among
different studies could be explained by the difference in study
design and setting.
The observed mortality rates for patients with MDR- and XDR-
TB (3.0% and 6.3%, respectively) in our study are relatively lower
than those reported by a few other studies evaluating early treatment
outcomes of patients with MDR- and XDR-TB. For example, in a
study conducted in Karakalpakstan, Uzbekistan in 2003–2005, 15%
of the 87 MDR-TB patients who were started on treatment during
that period died [16]. In another study analysing early treatment
outcomes of patients with XDR-TB in South Africa, 62 (36%) of the
174 patients with XDR-TB died, and the proportion of deaths was
not significantly different in patients with or without HIV infection
(41%, 34/82 versus 30%, 28/92) [18]. The difference in mortality
rates in patients who suffered from MDR- and XDR-TB as reported
in the above studies may be explained by clinical condition of the TB
patients, the treatment regimens and protocols they received as well
as the rates of defaulters in those studies.
The Cox proportional hazards model analysis that was
performed showed that having chronic obstructive pulmonary
disease and also hypertension were independent risk factors
associated with death among TB patients, and having MDR-TB
and cavitory disease were contributory to be risk factors associated
with death among TB patients. Those findings further confirmed
previous observation that pre-existing anti-TB drugs resistance
and poor clinical condition of TB patients are common risk factors
associated with death in TB patients [10,16,18].
Our study has several limitations. Firstly, some data on smoking
(4.6%), alcohol abuse (3.6%), lower lung field TB (7.5%), AFB
smear results at treatment onset (18.2%) and family history (2.0%)
were not available at the time the study was performed. Secondly,
this study was limited by the relatively small number of XDR-TB
cases which were included in the analysis. It is likely that a larger
patient cohort would have shown a more significant association
between poor treatment outcomes and certain variables, including
being migrants, having underlying diseases such as chronic
obstructive pulmonary disease and having abnormal liver function
for the XDR-TB patients. Thirdly, a relatively large proportion of
patients without available medical records might have introduced
a selection bias in our study. Those medical records were either
borrowed by medical staff for treatment purposes or were taken
away by those patients who were defaulted or were transferred out.
Since the prognosis for defaulted patients was suggested to be poor
[29], the fact that there were 188 of the 716 MDR-TB patients’
medical records missing in our analysis could lead to under-
estimation of poor treatment outcomes. We only had monitoring
data for further deaths in the studied patients at 2 years after
starting treatment, and no data was available on TB relapse and
the long-term outcomes such as death rates in .2 years following
the TB treatment. However, the long-term outcomes may be
much worse than the initial treatment outcomes which were
observed in our study, based on the data from the study in
Heilongjiang province of China [20], which reported that the
overall recurrence rates among new and retreatment MDR-TB
cases were 46% and 66% respectively, and the overall death rates
among new and retreatment MDR-TB cases were 25% and 46%
respectively 4 years following treatment, even though much higher
initial treatment success rates were observed in their study than
that in our study. Long-term follow up of the treatment outcomes
Table 7. Cox proportional hazards regression model of factors associated with risk of death in all TB patients (n = 3270)*.
Variables Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age
0–14 1 1
15–29 0.20 (0.03, 1.53) 0.121 0.22 (0.03, 1.74) 0.151
30–44 0.20 (0.03, 1.55) 0.123 0.16 (0.02, 1.25) 0.080
45–59 0.26 (0.03, 2.06) 0.204 0.25 (0.03, 2.02) 0.192
60–74 0.43 (0.06,3.35) 0.422 0.30 (0.04,2.40) 0.255
75– 0.45 (0.06, 3.66) 0.455 0.27 (0.03, 2.35) 0.236
Smear-positivity at treatment onset** 2.29 (1.03,5.08) 0.042 1.96 (0.86,4.44) 0.109
Cavitary disease 2.55 (1.42,4.58) 0.002 1.74 (0.95,3.19) 0.072
Chronic obstructive pulmonary disease 5.34 (2.74,10.44) ,0.001 5.25 (2.60,10.62) ,0.001
Hypertension 4.06 (1.97,8.36) ,0.001 4.31 (1.90,9.78) ,0.001
Not receiving 3 or more potentially effective drugs 1.76 (0.98,3.16) 0.058 1.30 (0.69,2.45) 0.413
MDR-TB 2.46 (1.36,4.46) 0.003 1.81 (0.96,3.41) 0.068
XDR-TB 4.36 (1.36,14.00) 0.013 2.20 (0.57,8.42) 0.251
TB = tuberculosis;
MDR=multidrug-resistant;
XDR = extensively drug-resistant.
HR = hazard ratio.
CI = confidence interval.
*Variables included in the univariate analysis were shown in Table S2; All variables with a P value,0.2 in the univariate analysis were included in multivariate Cox
regression analysis; A P value of ,0.05 was considered to be statistically significant.
**n = 2674.
doi:10.1371/journal.pone.0019399.t007
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for TB patients, especially for MDR- and XDR-TB patients, is
important. However, such follow-up study is difficult to conduct,
as only slightly more than half of patients were included in the
follow-up study in the Heilongjiang study, which may have
introduced bias into the estimation of the recurrence and death
rates, there is also the possibility of unreliable conclusions being
drawn from any data that is collected.
Despite these limitations, our study presents some useful
implications for basic research and clinical case management of
patients with MDR- and XDR-TB. As MDR- and XDR-TB
usually follow a much longer treatment course involving more
expensive, less effective and more toxic second- or third-line anti-
TB drugs, effort should be made to develop new and affordable
drugs with better efficacy and fewer side effects. For laboratory
diagnosis, economical and rapid molecular methods for the early
diagnosis of TB and the determination of drug resistance profiles
should be developed and applied to both new and retreated TB
cases to provide timely information with which appropriate
individualised regimens for MDR- and XDR-TB cases may be
developed. Clinically, more effort should be made to minimise the
number of defaulted patients. Greater measures should be taken to
provide adequate treatment for vulnerable populations such as
poor migrant TB patients and those who have serious underlying
diseases such as chronic obstructive pulmonary disease and
hypertension. In addition, more intensive efforts should be made
to manage MDR- and XDR-TB cases more effectively to improve
their treatment outcomes of all patients and hence minimise
further development of so-called totally drug-resistant TB cases
[35].
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